Natalie Banniettis

Dr. Natalie Banniettis


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KFKristen Feemster
Kristen Feemster
UBUlrike K Buchwald
Ulrike K Buchwald
NBNatalie Banniettis
Natalie Banniettis
JJJoseph G Joyce
Joseph G Joyce
PVPriscilla Velentgas
Priscilla Velentgas
IYInci Yildirim
Inci Yildirim
Global use of pneumococcal conjugate vaccines (PCVs) with increasingly broader serotype coverage has helped to reduce the burden of pneumococcal disease in children and adults. In clinical studies comparing PCVs, higher-valency PCVs have met noninferiority criteria (based on immunoglobulin G geometric mean concentrations and response rates) for most shared serotypes. A numeric trend of declining immunogenicity against shared serotypes with higher-valency PCVs has also been observed; however, the clinical relevance is uncertain, warranting additional research to evaluate the effectiveness of new vaccines. Novel conjugation processes, carriers, adjuvants, and vaccine platforms are approaches that could help maintain or improve immunogenicity and subsequent vaccine effectiveness while achieving broader protection with increasing valency in pneumococcal vaccines.

24 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
KFKristen Feemster
Kristen Feemster
JWJessica Weaver
Jessica Weaver
UBUlrike K Kirsten Buchwald
Ulrike K Kirsten Buchwald
NBNatalie Banniettis
Natalie Banniettis
KCKara S. Cox
Kara S. Cox
VSVana Spoulou
Vana Spoulou
Globally, Streptococcus pneumoniae is a leading cause of vaccine-preventable morbidity and mortality in infants and children. In recent decades, large-scale pediatric immunization programs have substantially reduced the incidence of invasive pneumococcal disease. Despite this, residual vaccine-type pneumococcal disease remains in the form of vaccine breakthrough and vaccine failure. This targeted literature review aims to discuss aspects of vaccine breakthrough and failure in infants and children, including disease epidemiology, clinical presentation, risk factors, vaccination schedules, vaccine serotypes, correlates of protection, comorbidities, disease surveillance, and potential implications for future vaccine development.

28 August 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
KFKristen Feemster
Kristen Feemster
WHWilliam Hausdorff
William Hausdorff
NBNatalie Banniettis
Natalie Banniettis
HPHeather Loryn Platt
Heather Loryn Platt
PVPriscilla T Velentgas
Priscilla T Velentgas
UBUlrike K Kirsten Buchwald
Ulrike K Kirsten Buchwald
Pneumococcal vaccines are a cornerstone for the prevention of pneumococcal diseases, reducing morbidity and mortality in children and adults worldwide. Pneumococcal vaccine composition is based on the polysaccharide capsule of Streptococcus pneumoniae, which is one of the most important identified contributors to the pathogen’s virulence. Similarities in the structural composition of polysaccharides included in licensed pneumococcal vaccines may result in cross-reactivity of immune response against closely related serotypes, including serotypes not included in the vaccine. Therefore, it is important to understand whether cross-reactive antibodies offer clinical protection against pneumococcal disease. This review explores available evidence of cross-reactivity and cross-protection associated with pneumococcal vaccines, the challenges associated with the assessment of cross-reactivity and cross-protection, and implications for vaccine design and development.

24 February 2023 in Vaccine
Verified
Journal Article
Open access
TBThomas Benfield
Thomas Benfield
MRMika Rämet
Mika Rämet
PVpiero valentini
piero valentini
ISIlkka Seppä
Ilkka Seppä
RDRon Dagan
Ron Dagan
JKJanusz Kaminski
Janusz Kaminski
This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F. Healthy infants were randomized to two primary doses and one toddler dose (2+1 regimen) of V114 or PCV13 at 3, 5, and 12 months of age; diphtheria, tetanus, pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib), hepatitis B (HepB) vaccine was administered concomitantly. Adverse events (AEs) were collected on Days 1-14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series, immediately prior to toddler dose, and 30 days post-toddler dose. Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for serotypes 22F and 33F. 1191 healthy infants were randomized to V114 (n = 595) or PCV13 (n = 596). Proportions of participants with solicited AEs and serious AEs were comparable between groups. V114 met non-inferiority criteria for 13 shared serotypes, based on difference in proportions with serotype-specific IgG ≥0.35 μg/mL (lower bound of two-sided 95% confidence interval [CI] >-10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5) at 30 days post-toddler dose. V114 met superiority criteria for serotypes 22F and 33F, based on response rates (lower bound of two-sided 95% CI >10.0) and IgG GMC ratios (lower bound of two-sided 95% CI >2.0) at 30 days post-toddler dose. Antibody responses to DTaP-IPV-Hib-HepB met non-inferiority criteria, based on antigen-specific response rates. A two-dose primary series plus toddler dose of V114 was well-tolerated in healthy infants. Compared with PCV13, V114 provided non-inferior immune responses to 13 shared serotypes and superior immune responses to additional serotypes 22F and 33F.

12 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MHMin Huang
Min Huang
JWJessica Weaver
Jessica Weaver
EEElamin Elbasha
Elamin Elbasha
TWThomas Weiss
Thomas Weiss
NBNatalie Banniettis
Natalie Banniettis
MKMatthew S. Kelly
Matthew S. Kelly
This study aimed to evaluate the cost-effectiveness of routine childhood immunization with the 20-valent pneumococcal conjugate vaccine (PCV20) in a four-dose regimen (3 + 1 schedule) versus the 15-valent PCV (PCV15/V114) in a three-dose regimen (2 + 1) in Germany. The study utilized a decision-analytic Markov model to estimate lifetime costs and effectiveness outcomes for a single birth cohort in Germany. The model tracked the incidence of acute pneumococcal infections and long-term pneumococcal meningitis sequelae for both vaccination strategies. The vaccine effectiveness data were derived from published clinical trials and observational studies of PCV7 and PCV13. Indirect effects, such as herd protection and serotype replacement, were included in the model. The model adopted a societal perspective, including direct medical, direct non-medical, and indirect costs. Scenario and sensitivity analyses were performed. In the base case, PCV20 prevented more pneumococcal disease cases and deaths, with an expected gain of 96 quality-adjusted life years (QALYs) compared to V114. However, PCV20 was associated with a total incremental cost of EUR 48,358,424, resulting in an incremental cost-effectiveness ratio (ICER) of EUR 503,620/QALY. Most of the scenario and sensitivity analyses estimated that the ICER for PCV20 exceeded EUR 150,000/QALY. Routine childhood immunization with PCV20 instead of V114 may not be an economically efficient use of healthcare resources in Germany.

13 December 2022 in Vaccine
Verified
Journal Article
Closed access
ABAndroniki Bili
Androniki Bili
SDScott Dobson
Scott Dobson
JQJeffrey Quinones
Jeffrey Quinones
WPWanatpreeya Phongsamart
Wanatpreeya Phongsamart
POPeninnah Oberdorfer
Peninnah Oberdorfer
KBKara Bickham
Kara Bickham